Patent: 7,893,021
✉ Email this page to a colleague
Summary for Patent: 7,893,021
Title: | Parathyroid hormone antagonists and uses thereof |
Abstract: | The present invention relates to parathyroid hormone (PTH) antagonists. More particularly, the present invention provides for pharmaceutical compositions, kits and combinations comprising the PTH antagonist. The present invention also provides for methods for preventing, treating or delaying a disease or disorder associated with excessive bone mineral, e.g., calcium, loss or for preventing, treating or delaying the effect of a PTH agonist using the PTH antagonist. The present invention further provides for methods for identifying a subject having or at risk of having osteoporosis or decreased bone density, or for identifying a subject in need of PTH antagonist treatment, or for monitoring a subject undergoing treatment for osteoporosis or decreased bone density, by determining and/or monitoring PTH antagonist level or a comparative value between PTH agonist and PTH antagonist. The present invention further provides for methods for identifying an agent suitable for preventing, treating or delaying osteoporosis by identifying a compound that enhances the PTH antagonist activity. |
Inventor(s): | Cantor; Thomas L. (El Cajon, CA) |
Assignee: | Scantibodies Laboratory, Inc. (Santee, CA) |
Application Number: | 10/215,770 |
Patent Claims: | see list of patent claims |
Details for Patent 7,893,021
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Nps Pharmaceuticals, Inc. | NATPARA | parathyroid hormone | For Injection | 125511 | 01/23/2015 | ⤷ Try a Trial | 2019-06-01 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |